Literature DB >> 1864017

Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus.

L W Moreland1, R E Gay, S Gay.   

Abstract

In order to determine whether collagen autoantibodies are present in sera from patients with vascular diseases, a highly sensitive solid-phase radioimmunoassay was utilized to evaluate the presence of antibodies against collagen types I to VI and laminin in sera of 20 patients with vasculitis and 20 patients with systemic lupus erythematosus (SLE). Autoantibodies to interstitial collagen types I and II were noted in 20 and 35% of the patients, respectively. Most significantly, 70% of the polyarteritis nodosa patients and 55% of the total vasculitis group had autoantibodies to collagen type IV. In SLE, autoantibodies to collagen type V were detected in 70% and to collagen type IV in 85% of the patient sera. These data indicate that basement membrane and basement membrane-associated collagens may become immunogenic in patients with vasculitis and SLE. The role of these autoantibodies is most likely a result of endothelial damage secondary to the initial inflammatory disease process. However, it can be concluded from the present studies that collagen types IV and V are involved in the immune response and thereby may perpetuate further vascular damage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864017     DOI: 10.1016/0090-1229(91)90097-t

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  8 in total

Review 1.  Autoantibodies against C1q: view on clinical relevance and pathogenic role.

Authors:  C E Siegert; M D Kazatchkine; A Sjöholm; R Würzner; M Loos; M R Daha
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  Prevalence and pathogenicity of autoantibodies in patients with idiopathic CD4 lymphopenia.

Authors:  Ainhoa Perez-Diez; Chun-Shu Wong; Xiangdong Liu; Harry Mystakelis; Jian Song; Yong Lu; Virginia Sheikh; Jeffrey S Bourgeois; Andrea Lisco; Elizabeth Laidlaw; Cornelia Cudrici; Chengsong Zhu; Quan-Zhen Li; Alexandra F Freeman; Peter R Williamson; Megan Anderson; Gregg Roby; John S Tsang; Richard Siegel; Irini Sereti
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

3.  Autoantibodies to types I and IV collagen and heart valve disease in systemic lupus erythematosus/antiphospholipid syndrome.

Authors:  José Pardos-Gea; Josefina Cortés-Hernández; Jesus Castro-Marrero; Eva Balada; José Ordi-Ros
Journal:  Clin Rheumatol       Date:  2017-03-10       Impact factor: 2.980

4.  An antibody profile of systemic lupus erythematosus detected by antigen microarray.

Authors:  Ittai Fattal; Noam Shental; Dror Mevorach; Juan-Manuel Anaya; Avi Livneh; Pnina Langevitz; Gisele Zandman-Goddard; Rachel Pauzner; Miriam Lerner; Miri Blank; Maria-Eugenia Hincapie; Uzi Gafter; Yaakov Naparstek; Yehuda Shoenfeld; Eytan Domany; Irun R Cohen
Journal:  Immunology       Date:  2010-02-26       Impact factor: 7.397

5.  Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies.

Authors:  C Mohan; L Morel; P Yang; H Watanabe; B Croker; G Gilkeson; E K Wakeland
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

Review 6.  Antiendothelial cells autoantibodies in vasculitis-associated systemic diseases.

Authors:  Philippe Guilpain; Luc Mouthon
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

7.  Human anti-fibronectin antibodies in systemic lupus erythematosus: occurrence and antigenic specificity.

Authors:  M S Atta; R J Powell; N D Hopkinson; I Todd
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

8.  Anti-endothelial cell antibodies in sera of patients with autoimmune diseases: comparison between ELISA and FACS analysis.

Authors:  J R Westphal; A M Boerbooms; C J Schalwijk; H Kwast; M De Weijert; C Jacobs; G Vierwinden; D J Ruiter; L B Van de Putte; R M De Waal
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.